Related Experiment Videos
Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial
1Dept Biopathol Clin, Hospital La Fe, Valencia, Spain.
Insights
Lovastatin effectively lowers plasma cholesterol in familial hypercholesterolemia patients. This treatment also improves red blood cell membrane composition and enhances blood flow properties.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Hematology
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels.
- Statins, like lovastatin, are primary treatments for FH, primarily targeting plasma lipid reduction.
- The impact of statin therapy on erythrocyte membrane lipid composition and hemorheology in FH patients remains less understood.
Purpose of the Study:
- To investigate the effects of lovastatin on erythrocyte membrane lipid composition.
- To determine if changes in erythrocyte membrane lipids correlate with alterations in red blood cell rheological behavior.
- To assess the overall hemorheological benefits of lovastatin treatment in FH patients.
Main Methods:
- A study involving fourteen FH patients treated with lovastatin (40 mg/day) for three months.
- Analysis of plasma lipid concentrations (cholesterol, LDL cholesterol).
- Measurement of erythrocyte membrane cholesterol/phospholipid ratio and assessment of red blood cell aggregability and filterability.
Main Results:
- Lovastatin significantly reduced plasma cholesterol and LDL cholesterol levels.
- A significant decrease in the erythrocyte membrane cholesterol/phospholipid ratio was observed (1.19 to 0.92, p < 0.01).
- These lipid composition changes correlated with reduced erythrocyte aggregability and improved blood filterability.
Conclusions:
- Lovastatin treatment in FH patients leads to favorable changes in erythrocyte membrane lipid composition.
- Alterations in red blood cell membrane lipids induced by lovastatin contribute to improved hemorheological parameters.
- Lovastatin therapy offers potential benefits beyond plasma lipid reduction, impacting blood rheology in FH patients.
Abstract:
Fourteen patients with familial hypercholesterolemia treated with lovastatin (40 mg/day) for three months were studied to find out whether the expected changes in plasma lipids are accompanied by modifications in the lipid composition of the erythrocyte membrane and whether these in turn induce changes in the rheological behavior of the red blood cell. Our results demonstrate the efficacy of lovastatin in reducing the plasma concentration of cholesterol and LDL cholesterol. The changes observed in the plasma lipids correlate with a significant decrease in the cholesterol/phospholipid ratio of the red blood cell membrane, from 1.19 +/- 0.19 in a basal situation to 0.92 +/- 0.23 (p < 0.01) at the end of treatment. These changes in the lipid composition of the cell are statistically related to a decrease in erythrocyte aggregability and an improvement in blood filterability, which means beneficial change in the patients' hemorheological situation.